ONCY News and Press, Oncolytics Biotech Inc. From 08/06/21

Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results Canada NewsWire - Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: ...

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference Presentation to take place on Thursday, August 12 at 1:30 p.m. ET Canada NewsWire SAN DIEGO and CALGARY, AB , Aug. 6, 2021 /CNW/ -- Onc...

Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference Presentation to take place on Wednesday, July 14 at 4:30 p.m. ET Canada NewsWire SAN DIEGO and CALGARY, AB , June 30, 2021 /CNW/ -- Oncolytics Biotech ® Inc. (NAS...

Stocks continue to rally in 2021. June is the sixth month in a row the TSX Composite Index has reached a fresh record high. Nonetheless, some tiny stocks still look undervalued. Bay Street analysts expect some of these stocks to more than double in the next 12 months. Most of these ...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Since the company’s inception in April of 1998, Oncolytics Biotech (TSX:ONC) (NASDAQ:ONCY) has been a development-stage company. The company has focused research and development efforts on a drug called pelareorep, a systemically administered immuno-oncology viral agent w...

Palm Beach, FL –May 20, 2021 – Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to trea...

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer The study achieved a 42% disease control rate in difficult-to-treat, second-line pancreatic cancer patients...

The global market for psychedelic drug treatments and therapy is in the early stages of what looks to be a massive shift. A growing wave of research has shown the power of psychedelics in offering effective treatments for mental health disorders such as depression, anxiety, and more. ...

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference PR Newswire Fireside chat to take place on Wednesday, May 19 at 5:25 pm ET SAN DIEGO and CALGARY, AB , May 13, 2021 /...